Annals of Oncology Advance Access published online on October 31, 2007
Annals of Oncology, doi:10.1093/annonc/mdm492
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
1 Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
2 Department of Medicine/Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA
3 CINECA-Interuniversity Consortium, Bologna, Italy
4 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
5 Department of Medical Oncology, Bellaria-Maggiore Hospital, Bologna
6 Department of Medical Oncology, San Matteo Hospital, Pavia
7 Department of Medical Oncology, Seconda Universita' di Napoli, Napoli
8 Pathology Unit, Milan University, Istituto Clinico Humanitas IRCCS, Rozzano
9 Department of Medical Oncology, Ospedale Silvestrini, Perugia, Italy
* Correspondence to: Dr F. Cappuzzo, Istituto Clinico Humanitas, via Manzoni 56, 20089-Rozzano, Italy. Tel: +39-02-82244097; Fax: +39-02-82244097; E-mail: federico.cappuzzo{at}humanitas.it
Background: Standardized conditions to distinguish subpopulations of colorectal cancer (CRC) patients more and less sensitive to cetuximab therapy remain undefined.
Materials and methods: We retrospectively analyzed epidermal growth factor receptor (EGFR) copy number by fluorescence in situ hybridization (FISH) in paraffin-embedded tumor blocks from 85 chemorefractory CRC patients treated with cetuximab. Results were analyzed according to different score systems previously reported in colorectal and lung cancers. The primary end point of the study was identification of the EGFR FISH score that best associates with response rate (RR).
Results: Using receiver operating characteristic (ROC) analysis, the cut-off that best discriminated responders versus nonresponders to cetuximab was a mean of 2.92 EGFR gene copies per cell. This model showed sensitivity of 58.6% [95% confidence interval (CI) = 47.1–70.1) and specificity of 93.3% (95% CI = 80.6–100). EGFR FISH-positive patients (N = 43, 50.6%) had significantly higher RR (P = 0.0001) and significantly longer time to disease progression (P = 0.02) than EGFR FISH negative (N = 42, 49.4%). Other scoring systems resulted less accurate in discriminating patients with the highest likelihood of response to cetuximab therapy.
Conclusions: CRC patients with high EGFR gene copy number have an increased likelihood to respond to cetuximab therapy. Prospective clinical trials with a careful standardization of assay conditions and pattern interpretation are urgently needed.
cetuximab, colon cancer, EGFR, fluorescence in situ hybridization
Received for publication August 10, 2007. Revision received September 18, 2007. Accepted for publication September 19, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Ann. Onc., September 1, 2009; 20(9): 1596 - 1603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Pintens, P Neven, M Drijkoningen, V Van Belle, P Moerman, M-R Christiaens, A Smeets, H Wildiers, and I V. Bempt Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1 J. Clin. Pathol., July 1, 2009; 62(7): 624 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Loupakis, L. Pollina, I. Stasi, A. Ruzzo, M. Scartozzi, D. Santini, G. Masi, F. Graziano, C. Cremolini, E. Rulli, et al. PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer J. Clin. Oncol., June 1, 2009; 27(16): 2622 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. -L. Garm Spindler, N. Pallisgaard, A. A. Rasmussen, J. Lindebjerg, R. F. Andersen, D. Cruger, and A. Jakobsen The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer Ann. Onc., May 1, 2009; 20(5): 879 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Martin, L Mazzucchelli, and M Frattini An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology J. Clin. Pathol., April 1, 2009; 62(4): 314 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, W. A. Messersmith, F. R. Hirsch, W. A. Franklin, and S. G. Eckhardt KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection J. Clin. Oncol., March 1, 2009; 27(7): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Laurent-Puig, A. Lievre, and H. Blons Mutations and Response to Epidermal Growth Factor Receptor Inhibitors Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer Ann. Onc., February 1, 2009; 20(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takano, S. Ota, A. Hori, N. Seki, and K. Eguchi Can Epidermal Growth Factor Receptor-Fluorescent in Situ Hybridization Predict Clinical Benefit From Cetuximab Treatment in Patients With Non-Small-Cell Lung Cancer? J. Clin. Oncol., January 20, 2009; 27(3): 464 - 465. [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr, M. Varella-Garcia, and D. R. Gandara In Reply J. Clin. Oncol., January 20, 2009; 27(3): 465 - 467. [Full Text] [PDF]
|
|
|
|
|
|
F. Perrone, A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann. Onc., January 1, 2009; 20(1): 84 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, et al. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5705 - 5712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Santini, F. Loupakis, B. Vincenzi, I. Floriani, I. Stasi, E. Canestrari, E. Rulli, P. E. Maltese, F. Andreoni, G. Masi, et al. High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice Oncologist, December 1, 2008; 13(12): 1270 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yonesaka, K. Zejnullahu, N. Lindeman, A. J. Homes, D. M. Jackman, F. Zhao, A. M. Rogers, B. E. Johnson, and P. A. Janne Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers Clin. Cancer Res., November 1, 2008; 14(21): 6963 - 6973. [Abstract] [Full Text] [PDF]
|
|